Filtered By:
Drug: Botox

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 134 results found since Jan 2013.

FDA Approves Botox for Lower Limb Spasticity FDA Approves Botox for Lower Limb Spasticity
The FDA has approved a new indication for Allergan's Botox (onabotulinumtoxinA): lower limb spasticity seen after stroke and in other neurologic disorders. FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - January 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Sensorimotor Modulation by Botulinum Toxin A in Post-Stroke Arm Spasticity: Passive Hand Movement
In post-stroke spasticity, functional imaging may uncover modulation in the central sensorimotor networks associated with botulinum toxin type A (BoNT) therapy. Investigations were performed to localize brain activation changes in stroke patients treated with BoNT for upper limb spasticity using functional magnetic resonance imaging (fMRI).
Source: Journal of the Neurological Sciences - January 11, 2016 Category: Neurology Authors: Tomáš Veverka, Petr Hluštík, Pavel Hok, Pavel Otruba, Jana Zapletalová, Zbyněk Tüdös, Alois Krobot, Petr Kaňovský Source Type: research

Real-World Data And Budget Impact Analysis for Incobotulinum Toxin A and Onabotulinum Toxin A for Upper Limb Post-Stroke Spasticity At A Uk Centre
Botulinum toxins (BT) are a valuable treatment option for patients with post-stroke upper-limb spasticity (PS-ULS), which affects 33,000 patients in the UK. Xeomin (incobotulinum toxin A) and Botox (onabotulinum toxin A) are two BTs licensed for the treatment of PS-ULS. The treatment costs for Xeomin and Botox will depend on their real-world usage.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Robertson, P Datta, J Kusel, S Page, J Soon Source Type: research

Plastic changes in spinal synaptic transmission following botulinum toxin A in patients with post-stroke spasticity.
CONCLUSION: Botulinum toxin treatment induces synaptic plasticity at the Ia-motoneuron synapse in post-stroke paretic patients, which suggests that the effectiveness of botulinum toxin-type A in post-stroke rehabilitation might be partly due to its central effects. PMID: 26424152 [PubMed - as supplied by publisher]
Source: Journal of Rehabilitation Medicine - October 3, 2015 Category: Rehabilitation Tags: J Rehabil Med Source Type: research

Efficacy and Safety of NABOTA in Post-stroke Upper Limb Spasticity: A phase 3 multicenter, double-blinded, randomized controlled trial
Botulinum toxin A is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (Onabotulinum toxin A). A total of 197 patients with post-stroke upper limb spasticity were included in this study and randomly assigned to NABOTA group (n=99) or Botox group (n=98). Wrist flexors with modified Ashworth Scale (MAS) grade 2 or greater, and elbow flexors, thumb flexors and finger flexors with MAS 1 or greater were injected with either drug.
Source: Journal of the Neurological Sciences - July 21, 2015 Category: Neurology Authors: Hyung Seok Nam, Yoon Ghil Park, Nam-Jong Paik, Byung-Mo Oh, Min Ho Chun, Hea-Eun Yang, Dae Hyun Kim, Youbin Yi, Han Gil Seo, Kwang Dong Kim, Min Cheol Chang, Jae Hak Ryu, Shi-Uk Lee Source Type: research

Physical therapy for an adult with chronic stroke after botulinum toxin injection for spasticity: a case report.
CONCLUSIONS: This case report demonstrates that physical therapy after BoNTA injections can result in significant functional improvements for individuals with spasticity after chronic stroke that may not be possible with BoNTA injections alone. PMID: 25931655 [PubMed]
Source: Physiotherapy Canada - May 3, 2015 Category: Physiotherapy Authors: Gallagher S, Phadke CP, Ismail F, Boulias C Tags: Physiother Can Source Type: research

Cortical activation changes and improved motor function in stroke patients after focal spasticity therapy– an interventional study applying repeated fMRI
Conclusions: Comprehensive focal spasticity management was also in this study associated with brain reorganization in a “normalizing” left/right lateralization direction in addition to improved motor function. Furthermore, quantification of BOLD intensity in specified BAs showed reduced neuronal “over-activity” in the injured brain after therapy.
Source: BMC Neurology - April 11, 2015 Category: Neurology Authors: Ulla BergfeldtTomas JonssonLennart BergfeldtPer Julin Source Type: research

Employment of Higher Doses of Botulinum Toxin Type A to Reduce Spasticity After Stroke
Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity with efficacy, reversibility, and low prevalence of complications. Current guidelines suggest a dose up to 600 units (U) of onabotulinumtoxinA/incobotulinumtoxinA or up to 1500 U of abobotulinumtoxinA to treat post-stroke spasticity to avoid important adverse effects. However, recently, higher doses of botulinum toxin type A were employed, especially in case of upper and lower limb severe spasticity.
Source: Journal of the Neurological Sciences - February 5, 2015 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Maurizio Ranieri, Giovanni Valeno, Antonio Albano, Alessio Baricich, Carlo Cisari, Domenico Intiso, Alberto Pilotto, Giancarlo Logroscino, Francesco Panza Source Type: research

Constraint-Induced Movement Therapy After Injection of Botulinum Toxin Type A for a Patient With Chronic Stroke: One-Year Follow-up Case Report.
DISCUSSION: The improved arm function could reflect improvements in volitional movements and coordination or speed of movements in the paretic arm that resulted from a reduction in spasticity, a reduction of learned nonuse behaviors, or use-dependent plasticity after the combination of BTX type A and constraint-induced movement therapy. If this approach proves useful in future controlled studies, this may halt the rising medical costs of the treatment of stroke. PMID: 25592185 [PubMed - as supplied by publisher]
Source: Physical Therapy - January 15, 2015 Category: Physiotherapy Authors: Amano S, Takebayashi T, Hanada K, Umeji A, Marumoto K, Furukawa K, Domen K Tags: Phys Ther Source Type: research

Accuracy of botulinum toxin type A injection into the forearm muscles of chronic stroke patients with spastic flexed wrist and clenched fist: Manual needle placement evaluated using ultrasonography.
CONCLUSION: Instrumental guidance should be used in order to achieve an acceptable accuracy of needle placement when performing botulinum toxin type A injections into the forearm muscles of chronic stroke patients with spastic flexed wrist and clenched fist. PMID: 25103251 [PubMed - in process]
Source: Journal of Rehabilitation Medicine - November 14, 2014 Category: Rehabilitation Tags: J Rehabil Med Source Type: research

Sensitivity of the NeuroFlexor method to measure change in spasticity after treatment with botulinum toxin A in wrist and finger muscles.
Conclusion: At the group level, the sensitivity of NeuroFlexor is good enough to detect reduction in spasticity after treatment with BoNT-A. Further work is needed to establish the sensitivity of NeuroFlexor on an individual level. PMID: 24850135 [PubMed - in process]
Source: Journal of Rehabilitation Medicine - November 14, 2014 Category: Rehabilitation Tags: J Rehabil Med Source Type: research

Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques
Botulinum toxin type A is a first-line treatment for post-stroke focal spasticity, and the accuracy in delivering the toxin to the target muscles may influence the treatment outcome. Our aim was to compare the reduction of spasticity and the related finger position at rest improvement in post-stroke patients treated with botulinum toxin type A in upper limb muscles using ultrasound guidance and manual needle placement.
Source: Journal of the Neurological Sciences - September 18, 2014 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Francesco Panza, Francesca Fortunato, Alessio Baricich, Carlo Cisari, Alberto Pilotto, Giancarlo Logroscino, Pietro Fiore, Maurizio Ranieri Source Type: research

Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: Real and imagined hand movement
Our aim was to use functional magnetic resonance imaging (fMRI) to compare brain activation changes due to botulinum toxin A (BoNT) application between two chronic stroke patient groups with different degree of weakness treated for upper limb spasticity.
Source: Journal of the Neurological Sciences - September 14, 2014 Category: Neurology Authors: Tomáš Veverka, Petr Hluštík, Pavel Hok, Pavel Otruba, Zbyněk Tüdös, Jana Zapletalová, Alois Krobot, Petr Kaňovský Source Type: research

Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic Rectus Femoris muscle of stroke patients with Stiff Knee Gait.
CONCLUSION: The percentage increase in peak knee flexion in swing during fast gait before injection is a useful predictor of the increase in peak knee flexion following RF BTX-A injection in chronic stroke patients with RF spasticity. PMID: 25213306 [PubMed - as supplied by publisher]
Source: European Journal of Physical and Rehabilitation Medicine - September 12, 2014 Category: Rehabilitation Authors: Roche N, Boudarham J, Hardy A, Bonnyaud C, Bensmail D Tags: Eur J Phys Rehabil Med Source Type: research

Heart rate variability (hrv) modifications in adult hemiplegic patients after botulinum toxin type a (nt-201) injection.
CONCLUSION: The use of incobotulinumtoxinA in adult patients at doses up to 12 units/kg seems to be safe regarding autonomic heart drive. CLINICAL REHABILITATION IMPACT: The use of IncobotulinumtoxinA up to 600 units could be a safe therapeutic option in spastic hemiplegic stroke survivors. PMID: 25051207 [PubMed - as supplied by publisher]
Source: European Journal of Physical and Rehabilitation Medicine - July 22, 2014 Category: Rehabilitation Authors: Invernizzi M, Carda S, Molinari C, Stagno D, Cisari C, Baricich A Tags: Eur J Phys Rehabil Med Source Type: research